Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6683148 | 1.00 | CYP2A6 (0.58) | CYP2A6KEAP1MAPTALDH1A1KDM4E | |
| SCHEMBL12804116 | 0.87 | CYP2A6 (0.44) | CYP2A6KEAP1MAPTALDH1A1KDM4E | |
| SCHEMBL8999779 | 0.82 | MAPT (0.57) | CYP2A6KEAP1MAPTALDH1A1KDM4E | |
| SCHEMBL12452461 | 0.81 | MAPT (0.59) | CYP2A6KEAP1MAPTALDH1A1KDM4E | |
| SCHEMBL14629866 | 0.81 | MAPT (0.55) | CYP2A6KEAP1MAPTALDH1A1KDM4E | |
| SCHEMBL21214072 | 0.80 | GAA (0.42) | CYP2A6KEAP1MAPTALDH1A1KDM4E | |
| SCHEMBL23278441 | 0.79 | MAPT (0.57) | CYP2A6KEAP1MAPTALDH1A1KDM4E | |
| SCHEMBL25629589 | 0.79 | BRD4 (0.54) | MAPTALDH1A1KDM4EHTTTDP1 | |
| SCHEMBL14310813 | 0.79 | MAPT (0.57) | CYP2A6KEAP1MAPTALDH1A1KDM4E | |
| SCHEMBL9414402 | 0.78 | MAPT (0.53) | CYP2A6KEAP1MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-112823157-B | Spirochroman derivatives | 吉瑞工厂 | 2024-08-09 | — | — | CN | disclosed |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | CYP2A6 283/4885KEAP1 426/4885MAPT 1125/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | CYP2A6 283/4885KEAP1 426/4885MAPT 1125/4885 |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | CYP2A6 283/4885KEAP1 426/4885MAPT 1125/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | CYP2A6 283/4885KEAP1 426/4885MAPT 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.